Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026)
Zoetis (ZTS) reported Liabilities and Shareholders Equity of $15.2 billion for Q1 2026, up 7.49% year-over-year from $14.1 billion in Q1 2025, and down 2.17% quarter-over-quarter from $15.5 billion in Q4 2025.
Zoetis (ZTS) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $15.2 billion in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $15.2 billion, up 7.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.3 billion (up 6.02% YoY), and the FY2025 annual result was $15.5 billion, up 8.8% from the prior year.
- Liabilities and Shareholders Equity eased to $15.2 billion in Q1 2026 per ZTS's latest filing, from $15.5 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $15.5 billion in Q4 2025 and troughed at $13.7 billion in Q3 2022.
- A 5-year average of $14.3 billion and a median of $14.2 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity decreased 4.28% in 2023, then rose 8.8% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $14.9 billion in 2022, then fell by 4.28% to $14.3 billion in 2023, then declined by 0.34% to $14.2 billion in 2024, then gained by 8.8% to $15.5 billion in 2025, then declined by 2.17% to $15.2 billion in 2026.
- Business Quant data shows ZTS's Liabilities and Shareholders Equity at $15.2 billion in Q1 2026, $15.5 billion in Q4 2025, and $15.2 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 40.04 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 15.15 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 6.71 Bn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 555.95 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 4.91 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 13.22 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.26 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 2.35 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 2.27 Bn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 401.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.15 Bn |
| Dec 31, 2025 | 15.49 Bn |
| Sep 30, 2025 | 15.16 Bn |
| Jun 30, 2025 | 14.48 Bn |
| Mar 31, 2025 | 14.10 Bn |
| Dec 31, 2024 | 14.24 Bn |
| Sep 30, 2024 | 14.36 Bn |
| Jun 30, 2024 | 14.17 Bn |
| Mar 31, 2024 | 14.35 Bn |
| Dec 31, 2023 | 14.29 Bn |
| Sep 30, 2023 | 14.11 Bn |
| Jun 30, 2023 | 13.75 Bn |
| Mar 31, 2023 | 13.75 Bn |
| Dec 31, 2022 | 14.93 Bn |
| Sep 30, 2022 | 13.67 Bn |
| Jun 30, 2022 | 13.77 Bn |
| Mar 31, 2022 | 13.86 Bn |
| Dec 31, 2021 | 13.90 Bn |
| Sep 30, 2021 | 13.71 Bn |
| Jun 30, 2021 | 14.07 Bn |